CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Arthur Kuan, the company's Chairman & CEO, is scheduled for a fireside chat on September 6, 2024, at 10:45 am ET in New York, NY.
CG Oncology focuses on developing a potential backbone bladder-sparing therapeutic for bladder cancer patients. Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.cgoncology.com. A replay of the webcast will be available for approximately 90 days after the live presentation concludes.
CG Oncology (NASDAQ: CGON), una società biopharmaceutica in fase avanzata, ha annunciato la sua partecipazione alla Morgan Stanley 22ª Conferenza Annuale Globale sulla Salute. Arthur Kuan, Presidente e CEO dell’azienda, è programmato per una chiacchierata informale il 6 settembre 2024, alle 10:45 ET a New York.
CG Oncology si concentra sullo sviluppo di una potenziale terapia per la conservazione della vescica per i pazienti con cancro alla vescica. Le parti interessate possono accedere alla trasmissione audio in diretta della presentazione nella sezione Relazioni con gli Investitori del sito web dell’azienda all’indirizzo www.cgoncology.com. Una registrazione della trasmissione sarà disponibile per circa 90 giorni dopo la conclusione della presentazione dal vivo.
CG Oncology (NASDAQ: CGON), una empresa biofarmacéutica en etapa avanzada, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. Arthur Kuan, el Presidente y CEO de la compañía, está programado para una charla informal el 6 de septiembre de 2024, a las 10:45 am ET en Nueva York, NY.
CG Oncology se enfoca en desarrollar una posible terapia que conserve la vejiga para pacientes con cáncer de vejiga. Los interesados pueden acceder a la transmisión de audio en vivo de la presentación desde la sección de Relaciones con Inversores en el sitio web de la compañía en www.cgoncology.com. Una repetición de la transmisión estará disponible por aproximadamente 90 días después de que concluya la presentación en vivo.
CG Oncology (NASDAQ: CGON), 후기 단계의 생물 의약품 회사가 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 아서 쿠안은 2024년 9월 6일 오전 10시 45분 ET에 뉴욕에서 파이어사이드 챗을 진행할 예정입니다.
CG Oncology는 방광암 환자를 위한 잠재적인 방광 보존 치료제를 개발하는 데 집중하고 있습니다. 관심 있는 분들은 회사 웹사이트의 투자자 관계 섹션에서 발표의 실시간 오디오 웹캐스트를 이용할 수 있습니다: www.cgoncology.com. 라이브 발표가 끝난 후 약 90일 동안 웹캐스트의 재생이 가능합니다.
CG Oncology (NASDAQ: CGON), une entreprise biopharmaceutique en phase avancée, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Arthur Kuan, le Président et CEO de l’entreprise, participera à une discussion informelle le 6 septembre 2024 à 10h45 ET à New York, NY.
CG Oncology se concentre sur le développement d'une thérapie potentiellement préservant la vessie pour les patients atteints de cancer de la vessie. Les parties intéressées peuvent accéder à la diffusion audio en direct de la présentation dans la section Relations Investisseurs du site web de l'entreprise à l'adresse suivante : www.cgoncology.com. Un enregistrement de la diffusion sera disponible pendant environ 90 jours après la fin de la présentation en direct.
CG Oncology (NASDAQ: CGON), ein biopharmazeutisches Unternehmen in der späten Klinikphase, hat seine Teilnahme an der 22. jährlichen Global Healthcare Conference von Morgan Stanley angekündigt. Arthur Kuan, der Vorsitzende und CEO des Unternehmens, ist für einen informellen Austausch am 6. September 2024 um 10:45 Uhr ET in New York, NY, eingeplant.
CG Oncology konzentriert sich auf die Entwicklung einer potenziellen blasen-schonenden Therapie für Blasen krebspatienten. Interessierte können die Live-Audio-Übertragung der Präsentation im Bereich Investor Relations auf der Unternehmenswebsite unter www.cgoncology.com abrufen. Eine Aufzeichnung der Übertragung wird etwa 90 Tage nach Abschluss der Live-Präsentation verfügbar sein.
- None.
- None.
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
VP, Communications and Patient Advocacy
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Laurence Watts
New Street IR
(619) 916-7620
IR@cgoncology.com
FAQ
When is CG Oncology (CGON) participating in the Morgan Stanley Healthcare Conference?
Who will represent CG Oncology (CGON) at the Morgan Stanley Healthcare Conference?
How can investors access CG Oncology's (CGON) presentation at the Morgan Stanley conference?
What is CG Oncology's (CGON) main focus in drug development?
How long will the webcast replay of CG Oncology's (CGON) presentation be available?
